Research use only is a label. Intended use is the bigger picture.

21 CFR §201.128 addresses the objective intent of the persons legally responsible for labeling drugs. That intent can be shown by labeling claims, advertising, oral or written statements, and the circumstances surrounding distribution. The regulation is not a certification program for research sellers, and citing it is not evidence that a product or business is approved.

The rule also contains a specific limitation concerning knowledge of an unapproved use by healthcare providers for an approved drug. That limitation should not be treated as a general exemption for the marketing of unapproved products. A qualified lawyer should assess how the rule applies to a particular product and distribution model.

In its December 10, 2024 letter to Summit Research Peptides, FDA described its review of the company’s website and social media. The agency stated that evidence from those websites established intended human use despite research-only labeling. This illustrates a practical point: a disclaimer can conflict with the surrounding promotional message.

FDA’s August 24, 2026 letter to NuScience Peptides likewise described violations identified through a website review. These are the agency’s stated findings in particular warning letters—not court judgments, a ruling about every RUO distributor, or proof of the recipients’ present compliance status. FDA cautions that subsequent correspondence can change the status of issues discussed in warning letters.

A product page cannot be assessed in isolation from the rest of the storefront. Educational pages, seller-controlled social accounts, promotional emails, imagery, and supporting statements can affect the overall message about a product’s intended use. A research-only footer does not erase contradictory advertising.

For distributors, the useful question is not “Did we add the correct sentence?” It is “Does the business consistently reflect the research-only purpose we claim?” Review substance, audience, actual practices, and surrounding context rather than replacing words while leaving the same consumer-facing offer in place.

• Review product titles, descriptions, images, and linked supporting pages.
• Check seller-controlled advertising and social content for inconsistent claims.
• Keep dated records of reviews, decisions, and substantive corrections.
• Escalate uncertain classifications and distribution practices to qualified counsel.

Verification gates, intended-use attestations, and website review records can support a documented compliance process. None independently establishes that a particular compound is lawful to sell or that a regulator or payment provider will accept the business.

SolRUO provides compliance and payment infrastructure for research-use-only distributors. Its whole-website scanning approach can help surface content for review; a scan is not legal advice, FDA approval, or a guarantee against restrictions. The distributor remains responsible for its products, claims, and operations.